Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer

Muhammad Shaalan Beg; Xiumei Huang; Molly A. Silvers; David E. Gerber; Joyce Bolluyt; Venetia Sarode; Farjana Fattah; Ralph J. Deberardinis; Matthew E. Merritt; Xian Jin Xie; Richard Leff; Daniel Laheru; David A. Boothman

doi:10.1002/jso.24624

Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer

Muhammad Shaalan Beg, Xiumei Huang, Molly A. Silvers, David E. Gerber, Joyce Bolluyt, Venetia Sarode, Farjana Fattah, Ralph J. Deberardinis, Matthew E. Merritt, Xian Jin Xie, Richard Leff, Daniel Laheru, David A. Boothman

Research output: Contribution to journal › Comment/debate › peer-review

24 Scopus citations

Abstract

Novel, tumor-selective therapies are needed to increase the survival rate of pancreatic cancer patients. K-Ras-mutant-driven NAD(P)H:quinone oxidoreductase 1 (NQO1) is over-expressed in pancreatic tumor versus associated normal tissue, while catalase expression is lowered compared to levels in associated normal pancreas tissue. ARQ761 undergoes a robust, futile redox cycle in NQO1+ cancer cells, producing massive hydrogen peroxide (H₂O₂) levels; normal tissues are spared by low NQO1 and high catalase expression. DNA damage created by ARQ761 in pancreatic cancer cells “hyperactivates” PARP1, causing metabolic catastrophe and NAD ± keresis cell death. NQO1: catalase levels (high in tumor, low in normal tissue) are an attractive therapeutic window to treat pancreatic cancer. Based on a growing body of literature, we are leading a clinical trial to evaluate the combination of ARQ761 and chemotherapy in patients with pancreatic cancer.

Original language	English (US)
Pages (from-to)	83-88
Number of pages	6
Journal	Journal of Surgical Oncology
Volume	116
Issue number	1
DOIs	https://doi.org/10.1002/jso.24624
State	Published - Jul 1 2017

Keywords

cancer metabolism
experimental therapeutics
hyperpolarization
pancreatic cancer
β-lapachone

ASJC Scopus subject areas

Surgery
Oncology

Access to Document

10.1002/jso.24624

Cite this

Beg, M. S., Huang, X., Silvers, M. A., Gerber, D. E., Bolluyt, J., Sarode, V., Fattah, F., Deberardinis, R. J., Merritt, M. E., Xie, X. J., Leff, R., Laheru, D., & Boothman, D. A. (2017). Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer. Journal of Surgical Oncology, 116(1), 83-88. https://doi.org/10.1002/jso.24624

Beg, MS, Huang, X, Silvers, MA, Gerber, DE, Bolluyt, J, Sarode, V, Fattah, F , Deberardinis, RJ, Merritt, ME, Xie, XJ, Leff, R, Laheru, D & Boothman, DA 2017, 'Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer', Journal of Surgical Oncology, vol. 116, no. 1, pp. 83-88. https://doi.org/10.1002/jso.24624

@article{1ac062dd5e1a431bac23556828dc8dc0,

title = "Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer",

abstract = "Novel, tumor-selective therapies are needed to increase the survival rate of pancreatic cancer patients. K-Ras-mutant-driven NAD(P)H:quinone oxidoreductase 1 (NQO1) is over-expressed in pancreatic tumor versus associated normal tissue, while catalase expression is lowered compared to levels in associated normal pancreas tissue. ARQ761 undergoes a robust, futile redox cycle in NQO1+ cancer cells, producing massive hydrogen peroxide (H2O2) levels; normal tissues are spared by low NQO1 and high catalase expression. DNA damage created by ARQ761 in pancreatic cancer cells “hyperactivates” PARP1, causing metabolic catastrophe and NAD ± keresis cell death. NQO1: catalase levels (high in tumor, low in normal tissue) are an attractive therapeutic window to treat pancreatic cancer. Based on a growing body of literature, we are leading a clinical trial to evaluate the combination of ARQ761 and chemotherapy in patients with pancreatic cancer.",

keywords = "cancer metabolism, experimental therapeutics, hyperpolarization, pancreatic cancer, β-lapachone",

author = "Beg, {Muhammad Shaalan} and Xiumei Huang and Silvers, {Molly A.} and Gerber, {David E.} and Joyce Bolluyt and Venetia Sarode and Farjana Fattah and Deberardinis, {Ralph J.} and Merritt, {Matthew E.} and Xie, {Xian Jin} and Richard Leff and Daniel Laheru and Boothman, {David A.}",

note = "Publisher Copyright: {\textcopyright} 2017 Wiley Periodicals, Inc.",

year = "2017",

month = jul,

day = "1",

doi = "10.1002/jso.24624",

language = "English (US)",

volume = "116",

pages = "83--88",

journal = "Journal of Surgical Oncology",

issn = "0022-4790",

publisher = "Wiley-Liss Inc.",

number = "1",

}

TY - JOUR

T1 - Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer

AU - Beg, Muhammad Shaalan

AU - Huang, Xiumei

AU - Silvers, Molly A.

AU - Gerber, David E.

AU - Bolluyt, Joyce

AU - Sarode, Venetia

AU - Fattah, Farjana

AU - Deberardinis, Ralph J.

AU - Merritt, Matthew E.

AU - Xie, Xian Jin

AU - Leff, Richard

AU - Laheru, Daniel

AU - Boothman, David A.

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Novel, tumor-selective therapies are needed to increase the survival rate of pancreatic cancer patients. K-Ras-mutant-driven NAD(P)H:quinone oxidoreductase 1 (NQO1) is over-expressed in pancreatic tumor versus associated normal tissue, while catalase expression is lowered compared to levels in associated normal pancreas tissue. ARQ761 undergoes a robust, futile redox cycle in NQO1+ cancer cells, producing massive hydrogen peroxide (H2O2) levels; normal tissues are spared by low NQO1 and high catalase expression. DNA damage created by ARQ761 in pancreatic cancer cells “hyperactivates” PARP1, causing metabolic catastrophe and NAD ± keresis cell death. NQO1: catalase levels (high in tumor, low in normal tissue) are an attractive therapeutic window to treat pancreatic cancer. Based on a growing body of literature, we are leading a clinical trial to evaluate the combination of ARQ761 and chemotherapy in patients with pancreatic cancer.

AB - Novel, tumor-selective therapies are needed to increase the survival rate of pancreatic cancer patients. K-Ras-mutant-driven NAD(P)H:quinone oxidoreductase 1 (NQO1) is over-expressed in pancreatic tumor versus associated normal tissue, while catalase expression is lowered compared to levels in associated normal pancreas tissue. ARQ761 undergoes a robust, futile redox cycle in NQO1+ cancer cells, producing massive hydrogen peroxide (H2O2) levels; normal tissues are spared by low NQO1 and high catalase expression. DNA damage created by ARQ761 in pancreatic cancer cells “hyperactivates” PARP1, causing metabolic catastrophe and NAD ± keresis cell death. NQO1: catalase levels (high in tumor, low in normal tissue) are an attractive therapeutic window to treat pancreatic cancer. Based on a growing body of literature, we are leading a clinical trial to evaluate the combination of ARQ761 and chemotherapy in patients with pancreatic cancer.

KW - cancer metabolism

KW - experimental therapeutics

KW - hyperpolarization

KW - pancreatic cancer

KW - β-lapachone

UR - http://www.scopus.com/inward/record.url?scp=85016470183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016470183&partnerID=8YFLogxK

U2 - 10.1002/jso.24624

DO - 10.1002/jso.24624

M3 - Comment/debate

C2 - 28346693

AN - SCOPUS:85016470183

SN - 0022-4790

VL - 116

SP - 83

EP - 88

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

IS - 1

ER -

Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this